TSHA
Taysha Gene Therapies, Inc.
$5.85
-2.01%
$1.7B
No data for this timeframe.
Vol
Market Cap$1.7B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (95%)
Inst. Holders50 funds
Inst. Value$843.4M
Inst. Activity11 buys / 5 sells
Insider Activity0B / 2S
Insider Net $-$899.5K
SEC Reports5
Press Releases3
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001806310·Prev Close $5.97
Recent Activity
Jun 16, 2026
short_volume
Short Volume: TSHA — 71.3% short (0.4M / 0.5M)
Short: 358,171 | Exempt: 0 | TRF Vol: 502,148 | Short Ratio: 71.3% | Off-exchange volume (dark pool
Jun 5, 2026
Press
Taysha Gene Therapies granted 714,700 RSUs and an option for 468,600 shares to four new employees under its 2023 Inducem
Impact 2/10
Jun 1, 2026
Insider
Long Alison S was granted 21,335 shares
Director
Jun 1, 2026
Insider
Stalfort John A III was granted 21,335 shares
Director
Jun 1, 2026
Insider
Long Alison S was granted 42,671 shares
Director
May 6, 2026
SEC
Taysha Gene Therapies reported Q1 2026 financial results with a net loss of $42.4M ($0.12/share), wider than the $21.5M
8-K — Impact 5/10
May 6, 2026
SEC
Taysha reported Q1 2026 EPS of -$0.12 (GAAP), wider than the -$0.08 consensus, with zero revenue vs $2.3M a year ago. Th
PRESS-RELEASE — Impact 7/10
Apr 29, 2026
SEC
Taysha Gene Therapies announced the date for its Q1 2026 earnings report and conference call on May 6, 2026. This is a r
PRESS-RELEASE — Impact 1/10
Price Targets
$12.23
+109.1% upside
Strong Buy
Current $5.85
Low $8.00
Median $12.00
High $19.00
13 analysts
$8.00
$19.00
Analyst Ratings
6Strong Buy
12Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 6, 2026 | Canaccord Genuity | MAINTAIN | Buy → Buy |
| Mar 19, 2026 | Chardan Capital | MAINTAIN | Buy → Buy |
| Mar 19, 2026 | Needham | MAINTAIN | Buy → Buy |
| Mar 3, 2026 | Needham | REITERATE | Buy → Buy |
| Jan 6, 2026 | Chardan Capital | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.11 ▲ +1.8% | $-0.12 — $-0.09 | -30% YoY | 4 |
| Next Q | $-0.12 | $-0.15 — $-0.09 | -39% YoY | 5 |
| Current FY | $-0.44 | $-0.52 — $-0.36 | -38% YoY | 5 |
| Next FY | $-0.44 | $-0.59 — $-0.37 | -1% YoY | 4 |
Latest Reports
NEUTRAL
Press
2/10
Taysha Gene Therapies granted 714,700 RSUs and an option for 468,600 shares to four new employees under its 2023 Inducem
Jun 5, 2026
NEUTRAL
8-K
5/10
Taysha Gene Therapies reported Q1 2026 financial results with a net loss of $42.4M ($0.12/share), wider than the $21.5M
May 6, 2026
MIXED
PRESS-RELEASE
7/10
Taysha reported Q1 2026 EPS of -$0.12 (GAAP), wider than the -$0.08 consensus, with zero revenue vs $2.3M a year ago. Th
May 6, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $105.3M | — |
| GOLDMAN SACHS GROUP INC | $100.0M | — |
| Avoro Capital Advisors LLC | $97.0M | — |
| BlackRock, Inc. | $82.1M | — |
| MORGAN STANLEY | $80.3M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 1, 2026 | Long Alison | A | $0.00 |
| Jun 1, 2026 | Stalfort John | A | $0.00 |
| Jun 1, 2026 | Long Alison | A | $0.00 |
| Jun 1, 2026 | Donenberg Phillip | A | $0.00 |
| Jun 1, 2026 | Donenberg Phillip | A | $0.00 |
50 institutional holders with $843.4M total value (188,897,191 shares) as of 2026-Q1. Top holders: RA, GOLDMAN, Avoro. Net buying activity: 11 institutions added/increased vs 5 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | 23,555,648 | $105.3M | 12.5% | — |
| 2 | GOLDMAN SACHS GROUP INC | 22,369,645 | $100.0M | 11.9% | — |
| 3 | Avoro Capital Advisors LLC | 21,700,000 | $97.0M | 11.5% | — |
| 4 | BlackRock, Inc. | 18,365,608 | $82.1M | 9.7% | — |
| 5 | MORGAN STANLEY | 17,965,371 | $80.3M | 9.5% | — |
| 6 | FMR LLC | 14,321,255 | $64.0M | 7.6% | — |
| 7 | RTW INVESTMENTS, LP | 13,680,248 | $61.2M | 7.3% | TRIM -32.7% |
| 8 | STATE STREET CORP | 11,209,078 | $50.1M | 5.9% | ADD +49.1% |
| 9 | VANGUARD CAPITAL MANAGEMENT LLC | 10,231,502 | $45.7M | 5.4% | — |
| 10 | Polar Capital Holdings Plc | 5,654,340 | $25.3M | 3.0% | TRIM -28.7% |
| 11 | D. E. Shaw & Co., Inc. | 4,427,301 | $19.8M | 2.3% | ADD +48.3% |
| 12 | BAKER BROS. ADVISORS LP | 4,004,756 | $17.9M | 2.1% | — |
| 13 | HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 2,883,301 | $12.9M | 1.5% | NEW |
| 14 | BARCLAYS PLC | 2,812,010 | $11.4M | 1.4% | DOUBLED +1042.8% |
| 15 | VANGUARD PORTFOLIO MANAGEMENT LLC | 2,022,498 | $9.0M | 1.1% | — |
| 16 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,808,599 | $8.1M | 1.0% | DOUBLED +275.5% |
| 17 | BANK OF AMERICA CORP /DE/ | 1,677,046 | $7.5M | 0.9% | ADD +45.5% |
| 18 | VANGUARD FIDUCIARY TRUST CO | 1,530,461 | $6.8M | 0.8% | — |
| 19 | TWO SIGMA INVESTMENTS, LP | 742,081 | $3.3M | 0.4% | DOUBLED +431.2% |
| 20 | WELLINGTON MANAGEMENT GROUP LLP | 626,361 | $2.8M | 0.3% | ADD +25.2% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| Polar Capital Holdings Plc | TRIM | 7,931,403 | 5,654,340 | -28.7% | $25.3M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | ADD | 1,152,680 | 1,677,046 | +45.5% | $7.5M | 2026-Q1 |
| VOYA INVESTMENT MANAGEMENT LLC | DOUBLED | 218,185 | 511,983 | +134.7% | $2.3M | 2026-Q1 |
| Point72 Asset Management, L.P. | NEAR_EXIT | 3,868,682 | 461,856 | -88.1% | $2.1M | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 171,100 | 413,203 | +141.5% | $1.8M | 2026-Q1 |
| Invesco Ltd. | TRIM | 1,332,780 | 368,021 | -72.4% | $1.6M | 2026-Q1 |
| POLEN CAPITAL MANAGEMENT LLC | DOUBLED | 156,586 | 319,748 | +104.2% | $1.4M | 2026-Q1 |
| STATE OF WISCONSIN INVESTMENT BOARD | DOUBLED | 113,178 | 263,332 | +132.7% | $1.2M | 2026-Q1 |
| PANAGORA ASSET MANAGEMENT INC | DOUBLED | 11,574 | 182,164 | +1473.9% | $814.3K | 2026-Q1 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | ADD | 67,085 | 99,371 | +48.1% | $444.2K | 2026-Q1 |
| BALYASNY ASSET MANAGEMENT L.P. | ADD | 42,070 | 83,019 | +97.3% | $371.1K | 2026-Q1 |
| PRUDENTIAL FINANCIAL INC | TRIM | 86,730 | 33,820 | -61.0% | $151.2K | 2026-Q1 |
| ENVESTNET ASSET MANAGEMENT INC | ADD | 20,178 | 33,654 | +66.8% | $150.4K | 2026-Q1 |
| Allworth Financial LP | DOUBLED | 223 | 5,443 | +2340.8% | $24.3K | 2026-Q1 |
| PRICE T ROWE ASSOCIATES INC /MD/ | ADD | 121,814 | 158,954 | +30.5% | $711.00 | 2026-Q1 |
| NORGES BANK | EXIT | 1,837,800 | 0 | -100.0% | $0.00 | 2026-Q1 |
| RTW INVESTMENTS, LP | TRIM | 24,354,291 | 16,398,297 | -32.7% | $90.2M | 2025-Q4 |
| STATE STREET CORP | ADD | 7,236,465 | 10,790,084 | +49.1% | $59.3M | 2025-Q4 |
| Polar Capital Holdings Plc | ADD | 5,293,879 | 7,931,403 | +49.8% | $43.6M | 2025-Q4 |
| D. E. Shaw & Co., Inc. | ADD | 2,706,434 | 4,013,635 | +48.3% | $22.1M | 2025-Q4 |
| Point72 Asset Management, L.P. | TRIM | 7,331,470 | 3,868,682 | -47.2% | $21.3M | 2025-Q4 |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | NEW | — | 3,722,000 | — | $20.5M | 2025-Q4 |
| NORGES BANK | NEW | — | 1,837,800 | — | $10.1M | 2025-Q4 |
| Invesco Ltd. | DOUBLED | 279,793 | 1,332,780 | +376.3% | $7.3M | 2025-Q4 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | TRIM | 3,328,000 | 1,328,000 | -60.1% | $7.3M | 2025-Q4 |
6 unique insiders with 11 transactions. Net insider value: -$899.5K ($0.00 bought, $899.5K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 1, 2026 | Long Alison S | Director | AWARD | 21,335 | — | — |
| Jun 1, 2026 | Stalfort John A III | Director | AWARD | 21,335 | — | — |
| Jun 1, 2026 | Long Alison S | Director | AWARD | 42,671 | — | — |
| Jun 1, 2026 | Donenberg Phillip B. | Director | AWARD | 21,335 | — | — |
| Jun 1, 2026 | Donenberg Phillip B. | Director | AWARD | 42,671 | — | — |
| Jun 1, 2026 | Sepp-Lorenzino Laura | Director | AWARD | 42,671 | — | — |
| Jun 1, 2026 | Stalfort John A III | Director | AWARD | 42,671 | — | — |
| Jun 1, 2026 | Sepp-Lorenzino Laura | Director | AWARD | 21,335 | — | — |
| Apr 10, 2026 | Nagendran Sukumar | President and Head of R&D | EXERCISE | 19,021 | $1.71 | $32.5K |
| Apr 10, 2026 | Nagendran Sukumar | President and Head of R&D | SELL | 200,000 | $4.46 | $892.0K |
| Feb 4, 2026 | Alam Kamran | CHIEF FINANCIAL OFFICER | SELL | 1,655 | $4.52 | $7.5K |
5 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 1 mixed, 4 neutral. Avg impact: 3.8/10.
NEUTRAL
8-K
5/10
Taysha Gene Therapies reported Q1 2026 financial results with a net loss of $42.4M ($0.12/share), wi
May 6, 2026
MIXED
PRESS-RELEASE
7/10
Taysha reported Q1 2026 EPS of -$0.12 (GAAP), wider than the -$0.08 consensus, with zero revenue vs
May 6, 2026
NEUTRAL
PRESS-RELEASE
1/10
Taysha Gene Therapies announced the date for its Q1 2026 earnings report and conference call on May
Apr 29, 2026
NEUTRAL
DEFA14A
3/10
Taysha Gene Therapies, Inc. is holding its 2026 Annual Meeting to vote on director elections, audito
Apr 22, 2026
NEUTRAL
144
3/10
Nagendran Sukumar, an officer of Taysha Gene Therapies, filed a Form 144 to notify intent to sell up
Apr 10, 2026
NEUTRAL
2/10
Taysha Gene Therapies granted 714,700 RSUs and an option for 468,600 shares to four new employees un
Jun 5, 2026
BULLISH
6/10
Taysha Gene Therapies announced positive preclinical in vitro data for TSHA-102, showing scAAV9 enab
Apr 27, 2026
MIXED
6/10
Taysha Gene Therapies reported financial results for 2025 and provided a corporate update highlighti
Mar 19, 2026
Current analyst consensus: Strong Buy (95% buy). Based on 19 analysts: 6 strong buy, 12 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$12.23 mean target
+109.1% upside
Strong Buy (1.23)
$8.00 Low
$19.00 High
| Metric | Value |
|---|---|
| Current Price | $5.85 |
| Target Low | $8.00 |
| Target Mean | $12.23 |
| Target Median | $12.00 |
| Target High | $19.00 |
| # Analysts | 13 |
| Recommendation | Strong Buy (1.23) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.11 | $-0.12 | $-0.09 | -30.3% | +1.8% | 1↑ 0↓ | $0.0B | -71.5% | 4 |
| Next Q 2026-09-30 |
$-0.12 | $-0.15 | $-0.09 | -39.5% | +0.0% | 1↑ 0↓ | $0.0B | 0.0% | 5 |
| Current FY 2026-12-31 |
$-0.44 | $-0.52 | $-0.36 | -38.4% | +0.0% | 2↑ 2↓ | $0.0B | -81.1% | 5 |
| Next FY 2027-12-31 |
$-0.44 | $-0.59 | $-0.37 | -0.6% | +0.0% | 0↑ 2↓ | $0.0B | 1512.6% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.110 | |
| 7d ago | $-0.110 | |
| 30d ago | $-0.112 | +0.002 |
| 60d ago | $-0.102 | -0.008 |
| 90d ago | $-0.105 | -0.005 |
4 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 6, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Mar 19, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Mar 19, 2026 | Needham | MAINTAIN | Buy | Buy |
| Mar 3, 2026 | Needham | REITERATE | Buy | Buy |
| Jan 6, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Jan 5, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 6 | 12 | 1 | 0 | 0 | 95% | |
| May 1, 2026 | 6 | 13 | 1 | 0 | 0 | 95% | |
| Apr 1, 2026 | 6 | 13 | 1 | 0 | 0 | 95% | |
| Mar 1, 2026 | 6 | 13 | 1 | 0 | 0 | 95% | |
| Feb 1, 2026 | 6 | 13 | 1 | 0 | 0 | 95% | |
| Jan 1, 2026 | 6 | 13 | 1 | 0 | 0 | 95% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 16, 2026
short_volume
Short Volume: TSHA — 71.3% short (0.4M / 0.5M)
Short: 358,171 | Exempt: 0 | TRF Vol: 502,148 | Short Ratio: 71.3% | Off-exchange volume (dark pool + OTC)
Jun 10, 2026
short_volume
Short Volume: TSHA — 61.7% short (0.3M / 0.5M)
Short: 309,432 | Exempt: 31 | TRF Vol: 501,832 | Short Ratio: 61.7% | Off-exchange volume (dark pool + OTC)
Jun 5, 2026
activist
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
<p>DALLAS, June 05, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology comp
May 14, 2026
short_volume
Short Volume: TSHA — 57.3% short (0.3M / 0.5M)
Short: 304,859 | Exempt: 0 | TRF Vol: 531,989 | Short Ratio: 57.3% | Off-exchange volume (dark pool + OTC)
May 8, 2026
short_volume
Short Volume: TSHA — 58.9% short (0.3M / 0.6M)
Short: 330,663 | Exempt: 3 | TRF Vol: 561,466 | Short Ratio: 58.9% | Off-exchange volume (dark pool + OTC)
May 7, 2026
short_volume
Short Volume: TSHA — 77.8% short (0.7M / 0.8M)
Short: 653,641 | Exempt: 62 | TRF Vol: 840,586 | Short Ratio: 77.8% | Off-exchange volume (dark pool + OTC)
May 6, 2026
earnings
Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update
<p align="left">DALLAS, May 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotec
May 6, 2026
short_volume
Short Volume: TSHA — 71.7% short (0.9M / 1.2M)
Short: 862,482 | Exempt: 707 | TRF Vol: 1,203,098 | Short Ratio: 71.7% | Off-exchange volume (dark pool + OTC)
May 6, 2026
earnings_calendar
TSHA Q1 2026 Earnings Scheduled — 2026-05-06
May 5, 2026
short_volume
Short Volume: TSHA — 68.5% short (0.4M / 0.6M)
Short: 421,633 | Exempt: 532 | TRF Vol: 615,774 | Short Ratio: 68.5% | Off-exchange volume (dark pool + OTC)
May 1, 2026
activist
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
<p align="left">DALLAS, May 01, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotec
Apr 30, 2026
short_volume
Short Volume: TSHA — 60.5% short (0.3M / 0.5M)
Short: 318,305 | Exempt: 0 | TRF Vol: 525,906 | Short Ratio: 60.5% | Off-exchange volume (dark pool + OTC)
Apr 29, 2026
earnings
Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6
<p>DALLAS, April 29, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology com
Apr 29, 2026
short_volume
Short Volume: TSHA — 63.0% short (0.6M / 0.9M)
Short: 584,486 | Exempt: 0 | TRF Vol: 927,783 | Short Ratio: 63.0% | Off-exchange volume (dark pool + OTC)
Apr 27, 2026
fda
Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting
<p align="center"><em>In vitro data demonstrated</em> <em>self-complementary AAV9 (scAAV9) enabled ~30-fold higher MeCP2 protein expression compared t